Americans lead the world in healthcare spending, yet they experience worsening health outcomes, including declining life expectancy. A significant portion of this expenditure is directed toward health insurance companies rather than direct healthcare services. The article discusses how deregulation has inflated pharmaceutical prices, particularly for rare diseases, allowing companies to charge premium prices due to the limited market. Although costs can be mitigated through generic medications, the rising expenses for specialized drugs create substantial financial burdens for consumers, influenced by research, development, and market factors.
Americans invest heavily in healthcare yet suffer diminishing returns; life expectancy is falling, with a large chunk of spending directed towards health insurance and pharmaceutical patents.
The high cost of medications in the U.S. can be attributed to factors such as production costs, research and development expenses, and the influence of deregulation within the pharmaceutical industry.
Collection
[
|
...
]